• StenoCare swung to negative EBITDA of DKK 244,000 in Q3 2026 from positive DKK 59,000 a year earlier.
• Net sales rose 53% year over year to DKK 2.94 million in the quarter.
• Nine-month net sales more than doubled to DKK 9.94 million from a year earlier.
• The 2026 figures include CannGros, while 2025 income statement comparisons cover StenoCare alone.
• German sales remained below expectations due to prescription and reimbursement changes affecting patient access.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. StenoCare A/S published the original content used to generate this news brief via Cision (Ref. ID: 20261028:BIT:1471:0) on October 29, 2026, and is solely responsible for the information contained therein.